Allergan PLC received Food and Drug Administration approval to market hyaluronic acid dermal filler Juvederm Vollure XC.
The company says the injectable gel, which treats moderate to severe facial wrinkles and folds, delivers results lasting up to 18 months—the “longest lasting result shown in a clinical study in the nasolabial folds,” it said in a press release. The product will be commercially available starting next month.
Chief Research and Development Officer David Nicholson said FDA’s approval of the new filler “demonstrates Allergan’s imperative to develop next-generation HA fillers designed to meet different patient needs.”
Allergan is chartered in Dublin, Ireland, and maintains U.S. campuses in Irvine and Parsippany, N.J.
Juvederm fillers are part of its Irvine operation that includes eye care, aesthetic medicine and therapeutic. Allergan traded recently at an $80 billion market cap.
